Tag Archives: over

FDA advisory panel split over Sanofi-Lexicon diabetes drug

(Reuters) – An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France’s Sanofi SA. The panel on Thursday voted 8-8 when asked to assess the once-daily oral medicine, sotagliflozin, an add-on to insulin therapy.… Read More »

As renewed debate over health care reform begins to simmer in Washington, can journalists give the topic the attention it needs?

Dec. 14th’s lower court ruling that the Affordable Care Act (ACA) is unconstitutional has again thrust health care back on the national agenda. It also gives journalists a chance to redeem themselves from what I have argued has been poor news coverage that helped fuel the public backlash against the law from the beginning. A lot… Read More »

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON (Reuters) – Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial. FILE PHOTO: An Amgen sign is seen at… Read More »